New treatments for chronic hepatitis C infection

被引：0

作者：

Yapali, Suna ^{[1
]}

Tozun, Nurdan ^{[1
]}

机构：

[1] Acibadem Univ, Sch Med, Subdept Gastroenterol & Hepatol, Kerem Aydinlar Kampusu,Kayisdagi Caddesi, Istanbul, Turkey

来源：

MARMARA MEDICAL JOURNAL | 2016年 / 29卷

关键词：

Hepatitis C; New treatments; Direct antiviral agents;

D O I：

10.5472/MMJsi.2901.09

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The goal of HCV treatment is to prevent cirrhosis, hepatocellular carcinoma, liver-related deaths. The development of direct-acting antiviral (DAA) agents which target various steps in HCV lifecycle led to a revolution by providing nearly complete eradication of HCV. The new treatment regimens with high cure rates have changed the standards of care in the regions where patients have access to new treatments. This review addresses the recent updates in management of chronic hepatitis C infection.

引用

页码：43 / 49

页数：7

共 29 条

[11] Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose [J].

Hadziyannis, SJ ;

Sette, H ;

Morgan, TR ;

Balan, V ;

Diago, M ;

Marcellin, P ;

Ramadori, G ;

Bodenheimer, H ;

Bernstein, D ;

Rizzetto, M ;

Zeuzem, S ;

Pockros, PJ ;

Lin, A ;

Ackrill, AM .

ANNALS OF INTERNAL MEDICINE, 2004, 140 (05) :346-355

[12] DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 3 INFECTION: INTERIM ANALYSIS OF A FRENCH MULTICENTER COMPASSIONATE USE PROGRAM [J].

Hezode, C. ;

De Ledinghen, V. ;

Fontaine, H. ;

Zoulim, F. ;

Lebray, P. ;

Boyer, N. ;

Larrey, D. ;

Silvain, C. ;

Botta-Fridlund, D. ;

Leroy, V. ;

Bourliere, M. ;

D'Alteroche, L. ;

Hubert-Fouchard, I. ;

Guyader, D. ;

Rosa, I. ;

Nguyen-Khac, E. ;

Di Martino, V. ;

Carrat, F. ;

Fedchuk, L. ;

Akremi, R. ;

Bennai, Y. ;

Bronowicki, J. -P. .

JOURNAL OF HEPATOLOGY, 2015, 62 :S265-S266

[13] Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options [J].

Jacobson, Ira M. ;

Gordon, Stuart C. ;

Kowdley, Kris V. ;

Yoshida, Eric M. ;

Rodriguez-Torres, Maribel ;

Sulkowski, Mark S. ;

Shiffman, Mitchell L. ;

Lawitz, Eric ;

Everson, Gregory ;

Bennett, Michael ;

Schiff, Eugene ;

Al-Assi, M. Tarek ;

Subramanian, G. Mani ;

An, Di ;

Lin, Ming ;

McNally, John ;

Brainard, Diana ;

Symonds, William T. ;

McHutchison, John G. ;

Patel, Keyur ;

Feld, Jordan ;

Pianko, Stephen ;

Nelson, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (20) :1867-1877

[14] Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection [J].

Jacobson, Ira M. ;

McHutchison, John G. ;

Dusheiko, Geoffrey ;

Di Bisceglie, Adrian M. ;

Reddy, K. Rajender ;

Bzowej, Natalie H. ;

Marcellin, Patrick ;

Muir, Andrew J. ;

Ferenci, Peter ;

Flisiak, Robert ;

George, Jacob ;

Rizzetto, Mario ;

Shouval, Daniel ;

Sola, Ricard ;

Terg, Ruben A. ;

Yoshida, Eric M. ;

Adda, Nathalie ;

Bengtsson, Leif ;

Sankoh, Abdul J. ;

Kieffer, Tara L. ;

George, Shelley ;

Kauffman, Robert S. ;

Zeuzem, Stefan .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (25) :2405-2416

[15] Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis [J].

Kowdley, Kris V. ;

Gordon, Stuart C. ;

Reddy, K. Rajender ;

Rossaro, Lorenzo ;

Bernstein, David E. ;

Lawitz, Eric ;

Shiffman, Mitchell L. ;

Schiff, Eugene ;

Ghalib, Reem ;

Ryan, Michael ;

Rustgi, Vinod ;

Chojkier, Mario ;

Herring, Robert ;

Di Bisceglie, Adrian M. ;

Pockros, Paul J. ;

Subramanian, G. Mani ;

An, Di ;

Svarovskaia, Evguenia ;

Hyland, Robert H. ;

Pang, Phillip S. ;

Symonds, William T. ;

McHutchison, John G. ;

Muir, Andrew J. ;

Pound, David ;

Fried, Michael W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) :1879-1888

[16] A PHASE 3, RANDOMISED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 8 AND 12 WEEKS OF SIMEPREVIR (SMV) PLUS SOFOSBUVIR (SOF) IN TREATMENT-NAIVE AND -EXPERIENCED PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION WITHOUT CIRRHOSIS: OPTIMIST-1 [J].

Kwo, P. ;

Gitlin, N. ;

Nahass, R. ;

Bernstein, D. ;

Rojter, S. ;

Schiff, E. ;

Davis, M. ;

Ruane, P. J. ;

Younes, Z. ;

Kalmeijer, R. ;

Peeters, M. ;

Lenz, O. ;

Fevery, B. ;

De La Rosa, G. ;

Scott, J. ;

Sinha, R. ;

Witek, J. .

JOURNAL OF HEPATOLOGY, 2015, 62 :S270-S270

[17] A PHASE 3, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 12 WEEKS OF SIMEPREVIR (SMV) PLUS SOFOSBUVIR (SOF) IN TREATMENT-NAIVE OR -EXPERIENCED PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION AND CIRRHOSIS: OPTIMIST-2 [J].

Lawitz, E. ;

Matusow, G. ;

DeJesus, E. ;

Yoshida, E. ;

Felizarta, F. ;

Ghalib, R. ;

Godofsky, E. ;

Herring, R. ;

Poleynard, G. ;

Sheikh, A. ;

Tobias, H. ;

Kugelmas, M. ;

Kalmeijer, R. ;

Peeters, M. ;

Lenz, O. ;

Fevery, B. ;

De La Rosa, G. ;

Scott, J. ;

Sinha, R. ;

Witek, J. .

JOURNAL OF HEPATOLOGY, 2015, 62 :S264-S265

[18] Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study [J].

Lawitz, Eric ;

Sulkowski, Mark S. ;

Ghalib, Reem ;

Rodriguez-Torres, Maribel ;

Younossi, Zobair M. ;

Corregidor, Ana ;

DeJesus, Edwin ;

Pearlman, Brian ;

Rabinovitz, Mordechai ;

Gitlin, Norman ;

Lim, Joseph K. ;

Pockros, Paul J. ;

Scott, John D. ;

Fevery, Bart ;

Lambrecht, Tom ;

Ouwerkerk-Mahadevan, Sivi ;

Callewaert, Katleen ;

Symonds, William T. ;

Picchio, Gaston ;

Lindsay, Karen L. ;

Beumont, Maria ;

Jacobson, Ira M. .

LANCET, 2014, 384 (9956) :1756-1765

[19]

Lawitz E, 2013, NEW ENGL J MED, V369, P678, DOI [10.1056/NEJMc1307641, 10.1056/NEJMoa1214853]

[20] Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].

Manns, MP ;

McHutchison, JG ;

Gordon, SC ;

Rustgi, VK ;

Shiffman, M ;

Reindollar, R ;

Goodman, ZD ;

Koury, K ;

Ling, MH ;

Albrecht, JK .

LANCET, 2001, 358 (9286) :958-965

← 1 2 3 →